AU6077899A - Skin and tissue care and/or treatment agent - Google Patents

Skin and tissue care and/or treatment agent Download PDF

Info

Publication number
AU6077899A
AU6077899A AU60778/99A AU6077899A AU6077899A AU 6077899 A AU6077899 A AU 6077899A AU 60778/99 A AU60778/99 A AU 60778/99A AU 6077899 A AU6077899 A AU 6077899A AU 6077899 A AU6077899 A AU 6077899A
Authority
AU
Australia
Prior art keywords
preparation according
preparation
peroxide
additionally comprises
metal salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU60778/99A
Other versions
AU761947B2 (en
Inventor
Herbert Schlachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MANDORLO INVESTMENT GmbH
Original Assignee
MANDORLO INVEST GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MANDORLO INVEST GmbH filed Critical MANDORLO INVEST GmbH
Publication of AU6077899A publication Critical patent/AU6077899A/en
Application granted granted Critical
Publication of AU761947B2 publication Critical patent/AU761947B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08Oxides; Hydroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/38Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22Peroxides; Oxygen; Ozone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A composition (I) containing (a) at least one salt selected from alkali metal salts, alkaline earth metal salts and other minerals, additionally contains (b) at least one aminoacid and (c) zinc oxide and/or an inorganic peroxide. ACTIVITY : Dermatological; antipsoriatic; antirheumatic; cytostatic; gastrointestinal. MECHANISM OF ACTION : (I) promotes diffusion of ions through ion channels into the intracellular space to improve microcirculation.

Description

Skin and tissue care and/or treatment preparation The invention relates to a skin and tissue care and/or treatment preparation. In particular, the invention relates to a preparation for care, protection and prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue, wherein said preparation comprises at least one salt selected from alkali and alkaline earth metal salts and other minerals and is characterized in that it contains at least one amino acid and zinc oxide and/or an inorganic peroxide, preferably magnesium peroxide or sodium peroxide. Optionally, the inventive preparation can additionally contain an adstringent, a binding and adhesive agent, a humectant, an ethereal oil, tego-betaine, secondary plant substances such as epigallocatechines, unsaturated fatty acids, liposomes, vitamins, trace elements and antifungal and/or antimicrobial components. Natural nutrients are essential for the health of cells and body. They serve to maintain and regenerate the skin as well as to stimulate metabolism and oxygen supply of the cells. The extensive significance of nutrient supply becomes also more and more important in the field of skin care, cosmetic and dermatology. Hormonal modifications, predisposition, an unbalanced and wrong diet and unhealthy. habits, especially smoking and lack of exercise, lead to typical manifestations of the skin, such as tissue modifications, tissue deformations and cellular metabolic disturbances. A well-aimed supply of nutrients harmonizes metabolism and thus results in a natural, physiological equilibrium of the cells. It is generally known that vitamins, minerals and trace elements are indispensable to the nutrient supply of the skin. Proteins which are built up of amino acids are an important building component for cells and endogenous active substances, such as enzymes and certain hormones. Polyunsaturated fatty acids, secondary plant substances, such as flavonoids and epigallocatechines, and liposomes in general are becoming more and more important for health and fitness. Vitamins, minerals and trace elements, polyunsaturated fatty acids and bioactive plant substances such as flavonoids are essential regulators in the metabolism and protective nutrients for the health of the skin. Vitamins are essential nutritional components which, for the normal functions of heterotrophic organisms, have to be supplied more or less obligatorily and in correspondence to the needs, since they are only available either from external 2 sources or under the influence of millieu factors (e.g. intestinal flora). Their specific biocatalytic effect is based on the replacement of the active groups of enzymes which are subject to metabolical consumption. From science it is for example known that B-type vitamins contribute to the intermediary metabolism as coenzymes and that vitamins C, E and p-carotene mainly function as antioxidants. Deficiencies resulting from insufficient supply or resorption, disorders of the intestinal flora or of metabolism, antivitamin-effect or increased consumption lead to hypovitaminosis and avitaminosis. Furthermore, minerals and trace elements are essential regulators in the metabolism. Zinc, magnesium and the B-type vitamins are high-performance elements -as they activate enzymes and thus allow the metabolism of carbohydrates, fats and protein substances. Silicon has a favorable effect on stability and maintenance of the skin. Furthermore, it is scientifically undisputed that zinc has an essential function in the immune system and in the metabolism of the skin. Polyunsaturated fatty acids contain linolic acid, and a- and y-linolenic acid, which are important starting substances for biologically active regulators in the metabolism, such as eicosanoids and prostaglandins, and which ensure a healthy equilibrium in the metabolism. Currently, eicosanoids and prostaglandins, also referred to as tissue hormones, are being intensively examined by scientists with regard to their health stabilizing effect. The favorable influence of the polyunsaturated fatty acids on the healthy skin function as well as on inflammatory processes is known. Furthermore, it is known that polyunsaturated fatty acids of the type of the co-3-(eicosapentaenoicacid, a-linolenic acid) and o-6-fatty acids (linolic acid, y-linolenic acid) have favorable effects on neurodermatitis and psoriasis as well as regeneration processes induced by physical strain during exercise. The importance of the so-called secondary plant substances, in the special branch of science also referred to as bioactive plant substances, for health is now being examined as well. Bioflavonoids, which effectively support the effects of vitamin C with regard to the power of resistance, vascular walls and connective tissue also count among these natural plant substances. Furthermore, it is known that bioflavonoids have antioxidant properties and that they thus synergistically complement the effect of the vitamins C, E and p-carotene.
3 With regard to biosynthesis aspects, amino acids are divided into essential, semi essential and non-essential amino acids. In addition to their function as building blocks for proteins, amino acids are precursors of biologically effective compo nds. Amino acids are i.a. described in L. Stryer, Biochemie, Spektrum Akadernischer Verlag, Oxford, 1994 and in Rbmpp Lexikon Chemie, editor J. Falbe and M. Regitz, keyword "amino acids", Thieme Verlag, 1996 and bibliographic references cited therein. Liposomes are particles surrounded by single or multi-layered phospholipid double membranes which can be loaded with hydrophilic pharmaceutical molecules in the inner, aqueous phase. By using them as pharmaceutical carriers, a selective local enrichment of active substances and a delayed release of active substances can be achieved. Numerous preparations for treating and preventing mycotic, microbic, pathologic and other tissue-damaging manifestations and effects, tissue modifications, tissue deformations and cellular metabolic disturbance and other forms of damage to human tissue are commercially available. There are, for example, various therapeutic approaches for treating skin and connective tissue problems. The success of many of these preparations is, however, questionable, as these preparations are unable to reach the damaged cells and/or to act in the damaged cells. Furthermore, many of the products that are commercially available do not take the active mechanism discovered by scientists into account in which the cell is remineralized in a natural way and metabolism is stimulated so that the natural inner pressure of the cell is reestablished, the cell volume is normalized and fat and slag substances are effectively displaced and secreted. DE-OS-196 22 708 describes a phytobiological preparation for the topical and parenteral incorporal application for preventing, caring for and treating various pathological and other endogenic and exogenic effects, modifications and diseases, as well as for maintaining, healing and reestablishing the homeostasis in and at animal and human organs and soft tissue, characterized in that it contains the following components: (a) one or more ion-containing components and mineral salts, (b) one or more adstringent components, one or more binding agents, a humectant and one or more ethereal oils, and 4 (c) optionally one or more vegetable extracts, a gelling agent, acid bondings, hyaluronidase or other suitable components in an amount between 0.01 and 20%. This preparation can optionally contain calendula, hamamelis or other homeopathic components, amino acids, enzymes, vitamins, electrolytes, dyes, wax, emulgators, starch, vaseline, paraffines, oils, acids, fats, vegetable mixtures and extracts, urea, sulfate compounds, etc. Neither does the patent application disclose examples of amino acids nor are amino acids used in the examples. An object'of the present invention is to provide a skin and tissue care and/or treatment preparation which distinguishes itself by a quick effect, excellent tolerance, a broad field of application and particularly intense deep action. In particular, the preparation is supposed to be applicable for care, protection, prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue. The preparation according to the invention is supposed to take into account research results concerning the diffusion of ions through ion channels into the intracellular space and improve microcirculation in the cell. An object of the present invention is solved by the provision of a composition comprising the following components: (a) at least one salt selected from alkali and alkaline earth metal salts and other minerals, characterized in that it contains (b) at least one amino acid, and (c) zinc oxide and/or an inorganic peroxide. Preferably zinc oxide, magnesium peroxide or sodium peroxide are used as component (c) of the composition. In preferred embodiments the inventive preparation can additionally comprise, each independent of the other, at least one adstringent agent, a humectant, an ethereal oil, tego-betaine, secondary plant substances such as flavonoids and epigallocatechines, unsaturated fatty acids, liposomes, vitamins, trace elements and antifungal and antimicrobial components. Furthermore, it can comprise usual carriers and adjuvants as well as binding and adhesive agents and usual solvents.
5 In a preferred embodiment the preparation of the present invention is topically used through direct application at the site of action. The preparation of the present invention takes into account new research results concerning the diffusion of ions through ion channels into the intracellular space. Hereby ions of mineral salts penetrate through the upper skin layers deep into the cell interior of hypoderm, connective tissue and fat cells. The inventive preparation uses i.a. the principle of ion exchange between cell interior and cell exterior using high osmotic pressure which is created by the combination of active substances of the preparation. In this process, however, the amino acids, which help the ions to more effectively overcome the natural barriers of the cell membranes to reach the cell interior, which is the actual site of action, play an important role. The inventive composition is in particular still effective if the functional capability of the cell regarding ion activity is limited. Particularly when the ion activity is limited, the amino.acids act as additional carriers for substances which must be infiltrated for the intracellular activity in order to be functionally effective therein. It has been found that the combination of amino acids and zinc oxide and/or inorganic peroxides improves the microcirculation in the cell, compared to the use of salts. The improvement can visually and biometrically be shown. If only salts are used, an increase of the microcirculation in the cell abruptly falls back to the starting value after about 1.5 hours. When the inventive composition comprising the combination of amino acids and zinc oxide and/or inorganic peroxides is used, the improvement of microcirculation is, compared to the use of salt, greater, more steady, lasts longer and approaches the starting value slowly. This allows a better infiltration of agents into and a better distribution of agents in the cell, which increases the synergistic effect. Furthermore, in contrast to the salts alone, a combination of salts and amino acids has a greater positive effect on the skin physiology. This affects in particular the moisturing factor, the pH value and the sebometry of the skin. When salts are used in combination with amino acids, the salts are infiltrated into the cell more effectively than without amino acids, as amino acids are, on the one hand, a key for the cell membranes and, on the other hand, support and increase the activation of the ion channels.
6 Alkali and alkaline earth metal salts and other minerals are essential regulators in the metabolism. In the present invention all known alkali and alkaline earth metal salts and minerals, which can also be present as trace elements, can be used. Preferred representatives of the group of alkali and alkaline earth metal salts and minerals that can be used in the present invention are sodium, potassium, magnesium, calcium, silicon, zinc, manganese, copper, iron, fluorine, chlorine, bromine, iodine and phosphorus. Preferred trace elements are accidental trace elements,.such as silver, gold, aluminum, barium, bismuth, cadmium, chrome, nickel, lead, tin, titanium and vanadium, and essential trace elements, such as chrome, cobalt, copper, fluorine, iron, iodine, manganese, molybdenum and selenium, which are present in, for example, enzymes, chromoproteines and hormones as constituents. The amount of the alkali and alkaline earth metal salts and other minerals in the inventive preparation is preferably 10 to 90 percent by weight, more preferably 20 to 85 percent by weight, particularly in topically applicable agents 10 to 30 percent by weight, more preferably 10 to 25 percent by weight, based on the sum of all components in the preparation, depending on the desired osmotic effect. The alkali and alkaline earth metal salts and the other minerals are added in the form of usual salt compounds or organic compounds. For example, sodium, potassium and magnesium are preferably added in the form of their chloride salts, sodium and calcium in the form of phosphates. The adstringent agents which are optionally used in the present invention comprise -usual compounds for this purpose. Tannin, hamamelis, rhubarb, rhatany, and salvia are preferably used as adstringent. The amount of the adstringent agents in the inventive preparation is preferably 0 to 30 percent by weight, more preferably 1 to 25 percent by weight, based on the sum of all components in the preparation. The adstringent agents are preferably added in a pure form. In the present invention usual humectants can optionally be used. Preferred humectants are glycerin, aloe vera, collagen, desamidocollagen, collagen hydrolysates, elastin hydrolysates, hyalomucco solution, fibrostimulin, PN 73, Q 10, water, aloe barbadensis gel, camelia sinensis extract, hedera helix, matricaria (camomile recutita) oil and butylene glykol. The amount of the humectants in the inventive preparation is preferably 0 to 70 percent by weight, more preferably 5 to 50 percent by weight, based on the sum of all components in the preparation.
7 Furthermore, the preparation of the present invention can optionally comprise usual ethereal oils. Preferred ethereal oils are oils of camomile, lavender, rosemary, camphor, mountain-pine, mint, tea tree and eucalyptus. The amount of the ethereal oils in the preparation of the present invention is preferably 0 to 70 percent by weight, more preferably 3 to 50 percent by weight, based on the sum of all components in the preparation. The ethereal oils are preferably added in a pure form or in the form of extracts or cold-drawn and warm-drawn oils. The preparation of the present invention can contain all known amino acids and amino acid derivatives. Preferred amino acids and amino acid derivatives are alanine, phenylalanine, cysteine, cystine, proline, tyrosine, serine, histidine, glycin, leucine, isoleucine, valine, tryptophan, arginine, lysin, asparagine and glutamine. Particularly cystine, cysteine, proline, serine, histidine, lycine, leucine, isoleucine, valine, tyrosine, arginine, lysin, asparagine and glutamine are used. Cystine, histidine, glycin, leucine, valine, arginine, lysin and glutamine are especially preferred. The D-form, DL-form and L-form of the amino acids can be used, whereby the L-form is preferred. Examples for amino acid derivatives are N acetylated forms, e.g. N-acetyl-L-glutamine, N-acetyl-L-tyrosine and N-acetyl-DL tryptophan. The amino acids and amino acid derivatives can be used solely or in the form of mixtures. The amount of amino acids and amino acid derivatives in the preparation of the present invention is preferably 0.1 to 40 percent by weight, more preferably 0.2 to 30 percent by weight, most preferably 0.2 to 15 percent by weight, based on the sum of all components in the preparation. The amino acids and their derivatives are preferably added in a pure form. The preparations of the present invention are furthermore characterized by the presence of zinc oxide and/or an inorganic peroxide. As inorganic peroxides preferably zinc peroxide, sodium peroxide, potassium peroxide, calcium peroxide or magnesium peroxide are used. Zinc oxide and/or an inorganic peroxide, for example, can be used to regulate the osmotic pressure. Surprisingly, the combination of amino acids with zinc oxide and/or an inorganic peroxide has a particularly good effect, compared to the use of magnesium peroxide alone. The total amount of zinc oxide and inorganic peroxide in the preparation of the present invention is preferably 0.5 to 50 percent by weight, more preferably 1.5 to 40 percent by weight, based on the sum of all components in the preparation. The amount of inorganic peroxide, if applied topically, should preferably not be larger 8 than 10 percent by weight, more preferably not larger than 6 percent by weight, most preferably not larger than 3 percent by weight, and, if applied internally, not larger than 20 percent by weight, more preferably not larger than 15 percent by weight. Zinc oxide and inorganic peroxide are preferably added in a pure form. Optionally, tego-betaine can additionally be present in the preparation of the present invention. The amount of tego-betaine in the inventive preparation is preferably 0 to 25 percent by weight, more preferably 1 to 20 percent by weight and most preferably 5 to 10 percent by weight based on the sum of all components in the preparation. Optionally, the preparation of the present invention can contain all known bioactive plant substances, also called secondary plant substances. The secondary plant substances used in the present invention particularly comprise carotinoids, phytosterols, saponins, polyphenols, flavonoids, terpenes, phytoestrogens, sulfides, phytin acid and dietary fiber. Of the above-mentioned bioactive plant substances particularly the polyphenols, the flavonoids and the bioflavonoids are used in the present invention. Bioflavonoids of natural sources are especially preferred in the inventive preparation. The bioactive plant substances can be present in the preferred embodiments of the preparation in a preferred amount of 0 to 75 percent by weight, more preferably 2 to 50 percent by weight, based on the sum of all components in the preparation. Preferred natural sources for the bioflavonoids are vegetables, such as pulses, carrots, tomatoes, broccoli and paprika, corn, sesame, citrus fruits, green and black tea, St. John's wort, grapes, etc. The bioactive plant substances are preferably added in the form of extracts. Optionally, all known unsaturated fatty acids can additionally be used in the preparation of the present invention. Preferably unsaturated fatty acids that are included in vegetable and animal oils (such as fish oil) are used. Polyunsaturated fatty acids from vegetable sources are essential precursors of important regulators of metabolism (eicosanoids and prostaglandines). The amount of unsaturated fatty acids in the inventive preparation is preferably 0 to 70 percent by weight, more preferably 2 to 45 percent by weight, based on the sum of all components in the preparation. Examples for preferred pure vegetable sources of unsaturated fatty acids are evening primrose oil, flax oil, olive oil, wheat germ oil, soy oil, sunflower oil, borage oil, pumpkin seed oil and oil of the seeds of the 9 redcurrant. The unsaturated fatty acids are preferably added in the form of cold drawn oils. Optionally, the preparation of the present invention can furthermore additionally contain usual liposomes, lecithin and lipodermine. Liposomes are important, as they control the release of vitamin A and vitamin E. That way these vitamins are accessible over a longer period of time. The amount of liposomes, lecithin or lipodermine in the inventive preparation is preferably 0 to 30 percent by weight, more preferably 2 to 20 percent by weight, based on the sum of all components in the preparation. Optionally, the preparation of the present invention can additionally comprise epigallocatechines, preferably recovered from green tea. Through epigallocatechines the aging of the cells can be delayed. Furthermore, they are important as cosubstances and serve to support the effect of micro nutrients, such as vitamins. The amount of the epigallocatechines in the preparation is preferably 0 to 60 percent by weight, more preferably 2 to 30 percent by weight, based on the sum of all components in the preparation. The epigallocatechines are preferably added in a pure form or as extracts. Optionally, the preparation of the present invention can additionally comprise all known representatives of vitamins and provitamins. Particularly vitamins A, those of the B-complex, C, D and E and p-carotine are preferably used in the preparation. The amount of the vitamins in the preparation of the present invention is preferably 0 to 75 percent by weight, more preferably 5 to 50 percent by weight, based on the sum of all components in the preparation. The vitamins are added both in a natural form as extracts and in a synthetic form (e.g. B vitamins), whereby differences in the effect of the vitamins are not linked with this fact. Optionally, the preparation of the present invention can additionally comprise antifungal and antimicrobial components. Antibiotics, bacteriostatics, corticosteroids, cortisones, econazol nitrate, dexametasone, hydroxy benzoate, etc. can be added to the inventive preparation. The amount of the antifungal and antimicrobial components in the preparation is preferably 0 to 60 percent by weight and most preferably 2 to 30 percent by weight, based on the sum of all components in the preparation.
10 Optionally, the preparation of the present invention can comprise all known adjuvants, additives and carrier substances, the usual binding and adhesive agents and solvents. Preferred examples are milk fat, unhydrogenated, partly hydrogenated or hydrogenated soy fat, soy oil, walnut butter, glycerin, gelatin, pectin, lecithin, P-carotenes, sorbitol solution, iron oxide, titanium dioxide, dyes, fats, waxes, emulgators (e.g. IRICALMIN of the company Pentafarm Ltd., CH), silicones, polyethylenes, polysorbitones, (meth)acryl compounds, talcum, dragantum, xanthan-gum, starch, vaseline, dextrose, saccharin, paraffins, acids, preservatives and fragrances. For example pectin can be used as binding and adhesive agent. Usual amounts of the above-mentioned substances and agents are used, e.g. pectin up to an amount of 10 percent by weight, based on the sum of all components in the preparation. The preparation of the present invention can be prepared in the usual manner known to every person skilled in the art, for example by combining the active ingredients with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and optionally the usual additives, adjuvants and solvents to a galenic form of administration. Methods for manufacturing galenic forms of administration, such as ointments and cremes, are for example described in H. Sucker, B. Fuchs, P. Speiser, "Pharmazeutische Technologie", 2 nd edition (1991), Georg Thieme Verlag Stuttgart; R. Voigt, "Lehrbuch der pharmazeutischen Technologie", Thieme Verlag, 1976. For the preparation of the present invention all known forms of application are possible. Preferred forms of application are creme, ointment, paste, emulsion, lotion, fluid, solution, gel, powder, spray, gelatin, foam and the like. Forms of application for internal application are for example capsules, tablets, coated tablets, drinking solutions and injection solutions, for example for hypodermal injections. A depot form as form of application is possible as well. In principle, all known modes of application are possible for the preparation of the present invention. The most preferred one is the topical application, for example effected by applying a corresponding form of application to the skin, e.g. by applying, rubbing on, rubbing gently in, spraying on, dabbing on, etc. Application is also possible in the form of ointment bandages or hypodermal injections. The preparation of the present invention can be applied once or several times a day and both over short and long periods of time. However, the daily dose and the 11 frequency of the application per day depends on the recipe of the individual inventive preparation. Depending on the recipe, the preparations of the present invention are suitable as food supplement, cosmetic or pharmaceutical composition, preferably as topical cosmetic or as topical pharmaceutical composition to be applied on the skin and tissue of mammals, and are for example used for the care, protection and prevention of tissue-damaging manifestations and effects and for the treatment of skin and tissue. Depending on their recipe, they are in a preferred embodiment particularly applicable to all skin irritations (e.g. disturbed skin physiology, sun burn), cellulitis, wrinkles, acne, herpes, psoriasis, neurodermatitis, ozone damage, burns, caustic burns, cellular metabolic disturbances and other modifications with accumulation of tissue fluid, fat and other cellular products and cellular catabolites, such as thickenings, edemas, hematomas, and are furthermore applicable to, for example, hemorrhoids, rheumatism, arthrosis, and skin cancer. The preparation can also be applied to mucous membranes, e.g. in the digestive system. The present invention is further illustrated by an example. Example I A preparation according to the invention having the following components was prepared in the usual manner: Zinc oxide 8 wt.-% Sodium peroxide 3 wt.-% Sodium phosphate 10 wt.-% Calcium phosphate 6 wt.-% Calcium chloride 5 wt.-% Arginine 7 wt.-% Leucine 8 wt.-% Asparagine 5.5 wt.-% Valine 2 wt.-% Hamamelis 1 wt.-% Tannin 3 wt.-% Pectin 1 wt.-% 12 Tego-betaine 2 wt.-% Vitamin A 1 wt.-% .Vitamin E 1.5 wt.-% p-carotine 0.5 wt.-% Collagen 1.5 wt.-% Aloe Vera 2 wt.-% Olive oil 2 wt.-% Carotinoids 2 wt.-% Gelatin 1 wt.-% Liposomes 2 wt.-% Purified water ad 100 wt.-% The composition of the above example was applied to one leg of probands. To the other leg control substances (placebo substances; control leg) are applied. The results of the examinations can be summarized as follows: As acute reaction of the above inventive recipe an increase of microcirculation was found.. After about 50 minutes a significant improvement of microcirculation was observed, whereby a maximum increase was reached after about 100 minutes. The significant effective phase was observed after about 120 minutes. On the control leg no changes in microcirculation were observed. As a further reaction caused by the application of the inventive recipe, a reduction of the fat layer on the treated leg could be observed, while there was no modification on the control leg. Through these examinations it was shown that the inventive preparation can significantly improve microcirculation and reduce the fat layer. Example 2 Amount (wt.-%) Aspargine 0.30 Leucine 0.20 Valine 0.30 Arginine - 0.20 Zinc peroxide 0.50 Calcium phosphate 4.50 Sodium phosphate 3.50 Zinc oxide transparent 2.00 13 Calcium chloride 4.00 Magnesium sulfate 3.00 Distilled water 62.90 Hamamelis 2.50 Tego-betaine 2.00 Sorbitol 6.00 Rosemary oil 0.30 Menthol 0.30 Green tea pulvis 1.00 Ivy/bottlebrush (horsetail)/algae/green tea 5.00 Xanthan-gum 1.50 The above inventive preparation was prepared in the usual manner. First, microcirculation on a specific skin area of a proband was measured. After that, the recipe of example 2 was rubbed gently into this skin area. Microcirculation was measured immediately and, after that, every half hour over a period of 4 hours. Hereby microcirculation was measured in flux units. The measuring results were plotted in relation to time. In comparison with a commercially available product which comprises salts and magnesium peroxide and which was, like the inventive preparation, applied to another skin area, it was observed that microcirculation rose earlier, maintained a higher level over a longer period of time and flattened to the starting value much later when the inventive recipe comprising a combination of certain amino acids and zinc oxide and zinc peroxide was used. The improvement compared to the commercial product was between 7 and 15 % at the corresponding measuring points. The results show the improved systemic, synergistic effect of the inventive recipe compared to the commercial product.
14 Example 3 A preparation according to the invention having the following components was prepared in the usual manner: Amount (wt.-%) Distilled water 71.15 Calcium phosphate 1.50 Leucine 0.20 Valine 0.30 Arginine 0.20 Aspargine 0.30 Zinc peroxide 0.25 Sodium phosphate 1.50 Zinc oxide transparent 3.00 Karion FP liquid 4.00 Neo Dragold liquid 0.30 Calcium chloride 1.50 Magnesium sulfate 2.50 Green tea pulvis 2.00 Calendula 3.00 Hamamelis 2.50 St. John's wort 3.00 Fragrance 1677 0.30 Teatree oil Australian 1.00 Xanthan-gum 1.50 15 Example 4 A preparation according to the invention having the following components was prepared in the usual manner: Amount (wt.-%) Distilled water 66.70 Zinc oxide transparent 2.00 Sodium phosphate 3.00 Aspargine 0.05 Calcium phosphate 3.50 Calcium chloride 3.50 Leucine 0.20 Magnesium sulfate 3.00 Zinc peroxide 0.30 Tego-betaine 2.00 Hamamelis 2.50 Sorbitol 5.00 YLANG-YLANG OIL 11 0.10 Lotus fragrance - ethereal oil mixture 0.10 Menthol 0.05 Green tea.pulvis 0.50 IRICALMIN 3.00 GLYCODERM 3.00 Xanthan-gum 1.50 In further applications of recipes which are part of the invention, significantly positive effects regarding aging, elasticity, moisture, wrinkling and tightening of the skin were observed.

Claims (10)

1. Preparation comprising the following components: (a) at least one salt selected from alkali metal salts, alkaline earth metal salts and other minerals, characterized in that it contains (b) at least one amino acid, and (c) zinc oxide and/or an inorganic peroxide.
2. Preparation according to claim 1, characterized in that it additionally comprises tego-betaine.
3. Preparation according to claim 1 or 2, characterized in that it additionally comprises at least one secondary plant substance and/or at least one epigallocatechine.
4. Preparation according to any one of claims 1 to 3, characterized in that it additionally comprises at least one unsaturated fatty acid and/or at least one trace element.
5. Preparation according to any one of claims 1 to 4, characterized in that it additionally comprises at least one liposome and/or at least one vitamin.
6. Preparation according to any one of claims 1 to 5, characterized in that it additionally comprises at least one adstringent agent and/or at least one humectant and/or at least one ethereal oil.
7. Preparation according to any one of claims 1 to 6, characterized in that it additionally comprises antifungal and/or antimicrobial components.
8. Preparation according to any one of claims I to 7, characterized in that it additionally comprises at least one component selected from carrier substances, adjuvants, additives, binding agents, adhesive agents and solvents.
9. Preparation according to any one of claims 1 to 8, comprising the following components:
17. (a) - 10 to 90 wt.-% of a salt, selected from alkali metal salts, alkaline earth metal salts and other minerals, characterized in that contains (b) 0.1 to 40 wt.-% of an amino acid, and (c) a total amount of zinc oxide and inorganic peroxide of 0.5 to 50 wt.-%, based on the sum of all components in the preparation. 10. Preparation according to any one of the claims 1 to 9, comprising the following components: (a) at least one metal salt selected from sodium, potassium, magnesium, calcium, silicon, zinc, manganese, copper, iron, fluorine, chlorine, bromine, iodine and phosphorus, characterized in that it contains (b) at least one amino acid or amino acid derivative selected from cystine, cysteine, proline, serine, histidine, glycin, leucine, isoleucine, valine, tyrosine, arginine, lysin, asparagine and glutamine, and (d) zinc oxide and/or an inorganic peroxide. 11. Preparation according to any one of claims 1 to 10, characterized in that the inorganic peroxide is zinc peroxide, sodium peroxide, potassium peroxide, calcium peroxide or magnesium peroxide. 12. Use of a preparation according to any one of claims 1 to 11 for topic application. 13. Use of a preparation according to claim 12 as a cosmetic. 14. Use of a preparation according to claim 12 as a pharmaceutical composition. 15. Use of a preparation according to any one of claims 1 to 11 as a pharmaceutical composition. 16. Use of a preparation according to any one of claims 1 to 11 as a food supplement.
AU60778/99A 1998-07-15 1999-07-15 Skin and tissue care and/or treatment agent Ceased AU761947B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19831798A DE19831798A1 (en) 1998-07-15 1998-07-15 Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement
DE19831798 1998-07-15
PCT/DE1999/002202 WO2000003689A2 (en) 1998-07-15 1999-07-15 Skin and tissue care and/or treatment agent

Publications (2)

Publication Number Publication Date
AU6077899A true AU6077899A (en) 2000-02-07
AU761947B2 AU761947B2 (en) 2003-06-12

Family

ID=7874155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60778/99A Ceased AU761947B2 (en) 1998-07-15 1999-07-15 Skin and tissue care and/or treatment agent

Country Status (18)

Country Link
EP (2) EP1096918B1 (en)
JP (1) JP3917370B2 (en)
KR (1) KR100542606B1 (en)
CN (1) CN1201723C (en)
AT (1) ATE308968T1 (en)
AU (1) AU761947B2 (en)
BR (1) BR9912821A (en)
CA (1) CA2337772C (en)
DE (3) DE19831798A1 (en)
DK (1) DK1096918T3 (en)
ES (1) ES2252976T3 (en)
HK (1) HK1037958A1 (en)
HU (1) HUP0103236A2 (en)
IL (1) IL140889A0 (en)
NO (1) NO20010220L (en)
PL (1) PL345689A1 (en)
WO (1) WO2000003689A2 (en)
ZA (1) ZA200101244B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011200202B2 (en) * 2004-02-23 2013-03-21 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
JP4532706B2 (en) * 2000-09-08 2010-08-25 花王株式会社 Cosmetics
DE10109798A1 (en) * 2001-03-01 2002-09-12 Aventis Pharma Gmbh Food additives for treatment or prevention of symptoms of diabetes, osteoarthritis, osteoporosis, asthma, mental decline and age related eye disease
DE10133203A1 (en) * 2001-07-07 2003-01-16 Beiersdorf Ag Topical compositions containing catechins and/or their gallate esters, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis
DE10133202A1 (en) * 2001-07-07 2003-01-16 Beiersdorf Ag Topical compositions containing osmolytes, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis
DE10243437A1 (en) * 2002-09-18 2004-04-29 Pm-International Ag Cosmetic formulation
US7480530B2 (en) 2003-06-30 2009-01-20 Johnson & Johnson Consumer Companies, Inc. Device for treatment of barrier membranes
US8734421B2 (en) 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
WO2005089803A2 (en) * 2004-03-24 2005-09-29 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
CA2563678A1 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
AT501221A1 (en) * 2005-01-14 2006-07-15 Hermine Dr Engl ACTIVE COMPOUND
EP2001435A1 (en) * 2006-03-22 2008-12-17 Takasago International Corporation Deodorant composition
CA2682507C (en) * 2007-04-09 2017-11-21 Wake Forest University Health Sciences Oxygen-generating compositions for enhancing cell and tissue survival in vivo
AU2013203151B2 (en) * 2007-04-09 2015-05-21 Wake Forest University Health Sciences Oxygen-generating compositions for enhancing cell and tissue survival in vivo
FR2916351B1 (en) * 2007-05-22 2012-12-07 Galderma Res & Dev PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS SELECTED BY PYRROLIDONE-5-CARBOXYLIC ACID, CITRULLINE, ARGININE AND ASPARAGINE AND THEIR USE IN THE TREATMENT OF ATOPIC DERMATITIS
JP5537046B2 (en) * 2009-02-20 2014-07-02 花王株式会社 Body rinse
US20120089232A1 (en) 2009-03-27 2012-04-12 Jennifer Hagyoung Kang Choi Medical devices with galvanic particulates
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
MX337166B (en) 2009-06-24 2016-02-15 Topical composition containing ibuprofen.
RU2548824C2 (en) 2009-11-13 2015-04-20 Джонсон Энд Джонсон Конзьюмер Компаниз, Инк. Galvanic device for skin treatment
CN105920603B (en) 2010-12-29 2022-02-11 战略科学与技术有限责任公司 Treatment of erectile dysfunction and other indications
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
CN102688483B (en) * 2011-03-22 2015-02-18 王成德 Composition for treating dermatosis, preparation containing composition and preparation method thereof
RU2457778C1 (en) * 2011-05-11 2012-08-10 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения и социального развития Российской Федерации Method of diagnosing disorder of microcirculation of small intestine in patients with diffuse peritonitis
DE102011109868A1 (en) * 2011-08-10 2013-02-14 STERNA BIOLOGICALS GmbH & Co. KG. Multiple emulsion
WO2014041528A2 (en) * 2012-09-14 2014-03-20 Martin Roslain Margaret A composition
EP2939670A4 (en) 2012-12-26 2016-12-21 A-Z Ltd Wound healing accelerator
CN104173232A (en) * 2014-08-06 2014-12-03 金玲 Method for preparing beautifying fluid capable of promoting skin resistance and repairing small-invasive skin
CN104189000A (en) * 2014-09-12 2014-12-10 朴荣范 Traumatism liquid medicine and preparation method thereof
WO2016128235A1 (en) * 2015-02-11 2016-08-18 Nestec S.A. Vitamin a composition
CN105901703B (en) * 2016-04-19 2020-03-10 上海海洋大学 Marine organism type enteral nutrition preparation for burn patients
EP3558244B1 (en) 2016-12-21 2022-02-23 Unilever IP Holdings B.V. Personal care compositions with cystine
EP3558246B1 (en) 2016-12-21 2021-10-20 Unilever IP Holdings B.V. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
CN110121331B (en) 2016-12-21 2022-09-16 联合利华知识产权控股有限公司 Personal care compositions containing poorly soluble compounds
CA3047495A1 (en) 2016-12-21 2018-06-28 Unilever Plc Topical skin lightening additive and composition with amino acids and nicotinamide compounds
CN112165927B (en) 2018-05-23 2024-01-30 联合利华知识产权控股有限公司 Nanoemulsion and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3861868A (en) * 1971-03-30 1975-01-21 Procter & Gamble Dyeing human hair with oxidation dyes and arginine or a protamine protein
DE2840498C2 (en) * 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmaceutical preparations for the treatment of psoriasis
US4283386A (en) * 1978-10-10 1981-08-11 Scott Eugene J Van Method for hair care
NZ223558A (en) * 1987-02-18 1990-04-26 Milor Scient Ltd Acne treatment composition
DE3905299C1 (en) * 1989-02-21 1990-08-09 Peter Prof. Dr.Med. 7980 Ravensburg De Klein
FR2651125B1 (en) * 1989-08-23 1992-10-02 Roussel Uclaf PHARMACEUTICAL COMPOSITIONS OF THE "WATER PASTE" TYPE.
BR9105986A (en) * 1990-02-05 1992-11-10 Univ Texas TIME-RELEASE FORMULATION OF VITAMINS, MINERALS AND OTHER BENEFICIAL SUPPLEMENTS
FR2674755B1 (en) * 1991-04-05 1995-02-03 Thorel Jean Noel NEW IMMUNOSTIMULATORY DRUG COMPOSITIONS.
US5681852A (en) * 1993-11-12 1997-10-28 The Procter & Gamble Company Desquamation compositions
FR2727014A1 (en) * 1994-11-18 1996-05-24 Rocher Yves Biolog Vegetale COSMETIC COMPOSITION AND METHOD FOR COMBATING DEAGREABLE BODILY ODORS PRODUCED BY PERSPIRATION
US5733535A (en) * 1995-10-25 1998-03-31 The Procter & Gamble Co. Topical compositions containing N-acetylcysteine and odor masking materials
US5597585A (en) * 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition
DE19622708A1 (en) * 1996-06-05 1997-12-11 Tomic Dobrivoje Aqueous compositions containing betaine
WO1998010741A1 (en) * 1996-06-27 1998-03-19 The Procter & Gamble Company Cosmetic compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011200202B2 (en) * 2004-02-23 2013-03-21 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance

Also Published As

Publication number Publication date
EP1096918A2 (en) 2001-05-09
DE19981295D2 (en) 2001-08-30
CA2337772C (en) 2009-06-09
PL345689A1 (en) 2002-01-02
DK1096918T3 (en) 2006-01-09
KR100542606B1 (en) 2006-01-11
ATE308968T1 (en) 2005-11-15
NO20010220L (en) 2001-03-13
DE59912774D1 (en) 2005-12-15
IL140889A0 (en) 2002-02-10
ZA200101244B (en) 2003-05-14
CN1313753A (en) 2001-09-19
NO20010220D0 (en) 2001-01-12
WO2000003689A2 (en) 2000-01-27
HK1037958A1 (en) 2002-03-01
JP3917370B2 (en) 2007-05-23
CN1201723C (en) 2005-05-18
ES2252976T3 (en) 2006-05-16
HUP0103236A2 (en) 2002-02-28
CA2337772A1 (en) 2000-01-27
EP1096918B1 (en) 2005-11-09
EP1639991A3 (en) 2007-09-05
EP1639991A2 (en) 2006-03-29
KR20010070965A (en) 2001-07-28
BR9912821A (en) 2001-05-02
AU761947B2 (en) 2003-06-12
WO2000003689A3 (en) 2000-04-20
JP2002520348A (en) 2002-07-09
DE19831798A1 (en) 2000-01-27

Similar Documents

Publication Publication Date Title
CA2337772C (en) Skin and tissue care and/or treatment agent
JP2002520348A5 (en)
ES2605405T3 (en) Compositions containing anti-acne agents and their use
US8017138B2 (en) Composition and method for treating skin
US5962482A (en) Method of reducing cellulite in mamalian skin
EP1667699B1 (en) Compositions comprising lotus extracts and methyl donors
DE69400353T2 (en) Slimming composition
EP1074245A2 (en) Composition using mineral salts for therapeutic treatment
JP7483331B2 (en) Compositions and methods for treating skin conditions using light and glucosamine hydrochloride
US20140271509A1 (en) Compositions for Skin Lightening and/or Brightening
EP0914138B1 (en) Complex preparations characterised by a betain content
US9682025B2 (en) Combination of active agents for oral administration for improving the quality of nails
MXPA01000485A (en) Skin and tissue care and/or treatment agent
EP4132459A1 (en) Composition for the making of an emulsifiable triphasic formulation, and kit for the use of such composition
CN112675094A (en) Plant extract, repairing composition, skin care product and preparation method thereof
KR101186096B1 (en) Oral compositions for the treatment of cellulite
CZ2001184A3 (en) Preparation for skin and tissue care
AU711191B2 (en) Preparations for use in cosmetics and dermatology
KR101851559B1 (en) Compositions for activating NGF and anti-aging cosmetic composition containing the same
CN1181811C (en) Superfine compound pearl powder cosmetic and its preparing process
KR20230060659A (en) Cosmetic composition for exfoliating and pad having the same
KR20010010655A (en) Composition for growthing hair
RU2351350C1 (en) Set "predstar", its application and method of prevention of premature organism aging
MXPA98010220A (en) Complex preparations characterized by beta content
Kvalheim et al. SKIN CARE PRODUCTS AND THEIR EFFECT ON AGING SKIN

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)